Celgene Corporation to Announce Second Quarter 2011 Results on July 28, 2011

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, July 28, 2011 at 9 a.m. ET to discuss the Company’s second quarter 2011 financial and operational results. The webcast will be available in the investor relations section of the Company’s Web site at www.celgene.com.

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company’s Web site at www.celgene.com.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts. Forward-looking statements generally are identified by the words "expects," "anticipates," "believes," "intends," "estimates," "aims," "plans," "will," "will continue," "seeks," “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those expressed in, or implied by, the forward-looking statements as a result of the impact of a number of factors, as well as other known and unknown risks and uncertainties, or if the assumptions underlying any of these statements prove incorrect. Certain of these factors are discussed in more detail in our Annual Report on Form 10-K filed with the Securities and Exchange Commission.



CONTACT:

Celgene Corporation
Jacqualyn Fouse, 908-673-9956
Senior Vice President and
Chief Financial Officer
or
Brian Gill, 908-673-9530
Vice President
Corporate Communications

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Professional Services  Banking  Finance  Research  Other Science  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.